Science Current Events | Science News | Brightsurf.com
 

Vaccine yielded encouraging long-term survival rates in certain patients with NSCLC

April 04, 2012
CHICAGO - Long-term follow-up of a phase II clinical trial showed encouraging survival in some patients with stage 3B/4 non-small cell lung cancer treated with belagenpumatucel-L, a therapeutic vaccine. The findings were presented here at the AACR Annual Meeting 2012, held March 31 - April 4.

"This is a novel immunotherapy that appears to show unusually long survival in some patients," said Lyudmila Bazhenova, M.D., associate clinical professor at the University of California-San Diego Moores Cancer Center in La Jolla, Calif.

These findings represent an updated long-term survival analysis on patients treated with belagenpumatucel-L, a cell-based allogeneic vaccine derived from four lung cancer cell lines. The open-label study included 75 patients with non-small cell lung cancer (NSCLC) - two patients with stage 2 disease, 12 with stage 3A, 15 with stage 3B and 46 with stage 4. The researchers randomly assigned patients to three dose cohorts: 1.25, 2.5 or 5 × 107 cells/injection.

For all patients, median survival was 14.5 months, and the five-year survival rate was 20 percent. The 40 patients with stage 3B/4 cancer enrolled in the second and third dose cohorts had a median survival of 15.9 months and a one-year survival rate of 61 percent, a two-year survival rate of 41 percent and a five-year survival rate of 18 percent.

Patients with stage 3B/4 nonprogressive disease after chemotherapy had a median survival of 44.4 months; five-year survival was 50 percent, which is "unheard of for patients with NSCLC," Bazhenova said.

In contrast, patients who progressed after front-line chemotherapy had a median survival rate of 14.1 months and a 9.1 percent five-year survival rate.

Bazhenova said that although these results are intriguing, they must be confirmed in a phase III clinical trial, which is currently under way in eight countries.

American Association for Cancer Research


Related Non-small Cell Lung Cancer Current Events and Non-small Cell Lung Cancer News Articles


Fast modeling of cancer mutations
Sequencing the genomes of tumor cells has revealed thousands of genetic mutations linked with cancer. However, sifting through this deluge of information to figure out which of these mutations actually drive cancer growth has proven to be a tedious, time-consuming process.

MD Anderson study first to compare treatments, survival benefits for early-stage lung cancer
Removal of the entire lobe of lung may offer patients with early-stage lung cancer better overall survival when compared with a partial resection, and stereotactic ablative radiotherapy (SABR) may offer the same survival benefit as a lobectomy for some patients, according to a study from The University of Texas MD Anderson Cancer Center.

Targeted treatment could halt womb cancer growth
A drug which targets a key gene fault could halt an aggressive womb cancer and shrink tumours, according to research published in the British Journal of Cancer.

NEJM: Crizotinib Effective in Phase 1 Trial Against ROS1 Lung Cancer
The New England Journal of Medicine reports positive results of a phase 1 clinical trial of the drug crizotinib against the subset of lung cancer marked by rearrangement of the gene ROS1.

Promising results shown with targeted approaches in subsets of non-small cell lung cancer
The BRAF inhibitor dabrafenib has significant anti-tumour activity in patients with advanced BRAF V600E mutant non-small cell lung cancer whose disease has progressed after chemotherapy, according to phase II data presented at the ESMO 2014 Congress in Madrid, Spain.

Docetaxel or pemetrexed with cisplatin achieve comparable outcomes in non-squamous Lu Ca
The first direct comparison of treating non-squamous lung cancer with either pemetrexed or docetaxel in addition to cisplatin has shown that the two combinations achieve similar progression-free survival, although docetaxel was associated with more frequent adverse events.

Customising chemotherapy in Lu Ca: New Ph II data reported in 2 LB studies
Measuring the expression levels of an enzyme involved in DNA synthesis can help predict the response of lung cancers to certain treatments, a Korean study has shown at the ESMO 2014 Congress in Madrid.

IMPRESS trial data on continuing tyrosine kinase inhibitor therapy after resistance development in lung cancer reported
Patients whose lung cancer has developed resistance to the drug gefitinib experience no statistically significant improvement in progression-free survival from continued treatment with the drug in addition to chemotherapy, a phase III trial presented at the ESMO 2014 Congress has shown.

Analysis finds select group of stage IV lung cancer patient population achieves long-term survival after aggressive treatments
A large, international analysis of patients with stage IV non-small cell lung cancer (NSCLC) indicates that a patient's overall survival (OS) rate can be related to factors including the timing of when metastases develop and lymph node involvement, and that aggressive treatment for "low-risk" patients leads to a five-year OS rate of 47.8 percent.

Patients with non-small cell lung cancer (NSCLC) who have never smoked or who have quit smoking have lower risk of developing secondary primary lung cancers than current smokers
Non-small cell lung cancer (NSCLC) survivors who never smoked or who are former smokers at the time of diagnosis have a lower risk of developing secondary primary lung cancers (SPLC) compared to those who are current smokers, suggesting that increased tobacco exposure is associated with a higher risk of SPLC.
More Non-small Cell Lung Cancer Current Events and Non-small Cell Lung Cancer News Articles

Non-Small Cell Lung Cancer: Across the Continuum of Care

Non-Small Cell Lung Cancer: Across the Continuum of Care
by Asante Communications, LLC


This Clinical Resource Tool is structured around consensus statements developed by the Non-Small Cell Lung Cancer (NSCLC) Working Group, a panel of oncologists with particular expertise in the multidimensional care of patients with advanced lung cancer. Using a modified Delphi process, the NSCLC Working Group has consolidated published evidence and expert clinical experience on critical issues pertaining to the comprehensive assessment of patients with advanced NSCLC, formulation of appropriate treatment regimens, implementation of maintenance therapy, and therapeutic alliances among pathologists, oncologists, and pulmonologists. The consensus statements and accompanying resources are intended as a practical companion to current guidelines, helping clinicians individualize best-practice...

Medifocus Guidebook on: Small Cell Lung Cancer

Medifocus Guidebook on: Small Cell Lung Cancer
by Medifocus.com (Author), Elliot Jacob PhD. (Editor)


The MediFocus Guidebook on Small Cell Lung Cancer is the most comprehensive, up-to-date source of information available. You will get answers to your questions, including risk factors of Small Cell Lung Cancer, standard and alternative treatment options, leading doctors, hospitals and medical centers that specialize in Small Cell Lung Cancer, results of the latest clinical trials, support groups and additional resources, and promising new treatments on the horizon. This one of a kind Guidebook offers answers to your critical health questions including the latest treatments, clinical trials, and expert research; high quality, professional level information you can trust and understand culled from the latest peer-reviewed journals; and a unique resource to find leading experts,...

What You Need to Know About Non-Small Cell Lung Cancer - It's Your Life, Live It!

What You Need to Know About Non-Small Cell Lung Cancer - It's Your Life, Live It!
by Cancer Group Institute


Selecting the right treatment can literally make the difference between life and death. It is important to have the peace-of-mind knowing that you have done everything possible to help fight Non-Small Cell Lung cancer successfully.

The Cancer Group Institute's book explains, in plain English, the definition, types, frequency, risk factors, symptoms, historic and latest effective treatment for Non-Small Cell Lung cancer. We describe surgery, radiation, chemotherapy and immune therapies. We tell you everything you must know to help make the right choices today for a Non-Small Cell Lung cancer problem.

We are honored to inform you that many leading hospitals use our books in their medical library to be used by physicians. They are Harvard University, Columbia, NYU, ...

What You Need to Know About Small Cell Lung Cancer - It's Your Life, Live It! (Volume 1)

What You Need to Know About Small Cell Lung Cancer - It's Your Life, Live It! (Volume 1)
by Michael Braham (Author)


Selecting the right treatment can literally make the difference between life and death. It is important to have the peace-of-mind knowing that you have done everything possible to help fight Small Cell Lung cancer successfully. The Cancer Group Institute's book explains, in plain English, the definition, types, frequency, risk factors, symptoms, historic and latest effective treatment for Small Cell Lung cancer. We describe surgery, radiation, chemotherapy and immune therapies. We tell you everything you must know to help make the right choices today for a Small Cell Lung cancer problem. Some of the Department Heads, Hospitals and Residents using our materials are Mayo Clinic, Harvard University, Columbia, NYU, UCLA, Johns Hopkins, MD Anderson Cancer Center Orlando, Tift Regional...

Non-Small Cell Lung Cancer: New Research (Cancer Etiology, Diagnosis and Treatments)

Non-Small Cell Lung Cancer: New Research (Cancer Etiology, Diagnosis and Treatments)
by Lina Pasquariello (Editor)




Medifocus Guidebook on: Non-Small Cell Lung Cancer

Medifocus Guidebook on: Non-Small Cell Lung Cancer
by Medifocus.com (Author), Elliot Jacob PhD. (Editor)


The MediFocus Guidebook on Non-Small Cell Lung Cancer is the most comprehensive, up-to-date source of information available. You will get answers to your questions, including risk factors of Non-Small Cell Lung Cancer, standard and alternative treatment options, leading doctors, hospitals and medical centers that specialize in Non-Small Cell Lung Cancer, results of the latest clinical trials, support groups and additional resources, and promising new treatments on the horizon. This one of a kind Guidebook offers answers to your critical health questions including the latest treatments, clinical trials, and expert research; high quality, professional level information you can trust and understand culled from the latest peer-reviewed journals; and a unique resource to find leading experts,...

Living With A Diagnosis Of Lung Cancer

Living With A Diagnosis Of Lung Cancer
by Joan Schiller MD (Author)


"Living With a Diagnosis of Lung Cancer” is an easy-to-understand booklet written to help lung cancer patients understand their diagnosis and their options as they face the disease. Lung cancer claims more lives than breast, prostate, and colon cancers combined. In fact, over 288,000 people are diagnosed each year in the U.S. People with lung cancer often are told, "Get your affairs in order." But, there is hope for those diagnosed with lung cancer. Thanks to research advances, there are options available to patients diagnosed regardless of the stage of the disease. Much progress is being made with new treatments being developed and tested each day. This valued resource will help you know what questions to ask of your medical team and can help you understand your treatments...

Systemic Treatment of Non-Small Cell Lung Cancer (Oxford Oncology Library)

Systemic Treatment of Non-Small Cell Lung Cancer (Oxford Oncology Library)
by Giuseppe Giaccone (Author)


Lung cancer is the leading cause of cancer mortality worldwide, and non-small cell lung cancer (NSCLC) accounts for about 85% of all cases of lung cancer. Most patients present with advanced disease and five-year survival is low at about 15%. Surgery is the main treatment for early stage disease. If patients are deemed inoperable, systemic chemotherapy is considered. For patients with locally advanced disease, multimodality therapy is administered where chemotherapy is given in combination with definitive radiation therapy or surgery in selected cases. Cytotoxic chemotherapy regimens mainly consist of a platinum doublet. Biologic agents are increasingly being incorporated into treatment regimens.

This pocketbook summarises the latest evidence-based and practical information on the...

21st Century Adult Cancer Sourcebook: Non-Small Cell Lung Cancer (NSCLC) - Clinical Data for Patients, Families, and Physicians

21st Century Adult Cancer Sourcebook: Non-Small Cell Lung Cancer (NSCLC) - Clinical Data for Patients, Families, and Physicians
by Progressive Management


Authoritative information and practical advice from the nation's cancer experts about non-small cell lung cancer (NSCLC) includes official medical data on signs, symptoms, early detection, diagnostic testing, risk factors and prevention, treatment options, surgery, radiation, drugs, chemotherapy, staging, biology, prognosis, and survival, with a complete glossary of technical medical terms and current references.

Starting with the basics, and advancing to detailed patient-oriented and physician-quality information, this comprehensive in-depth compilation gives empowered patients, families, caregivers, nurses, and physicians the knowledge they need to understand the diagnosis and treatment of non-small cell lung cancer (NSCLC).

Non-small cell lung cancer is a disease...

Targeted Therapy in Non-small Cell Lung Cancer (Oxford American Pocket Notes)

Targeted Therapy in Non-small Cell Lung Cancer (Oxford American Pocket Notes)
by David E. Gerber (Author)


Although lung cancer remains the leading cancer killer in the United States, recent years have seen a number of developments that may portend future clinical benefit. These include renewed interest in CT-based screening approaches, the use of stereotactic radiation for early stage tumors, proposed revisions to the lung cancer staging system, and the development of molecular methods to predict chemotherapy sensitivity. Perhaps the most significant advance in the treatment of this challenging disease is the introduction of molecularly targeted therapies, a term that includes monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs). Specifically, drugs targeting the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) are now FDA-approved for...

© 2014 BrightSurf.com